Wegovy
The Ozempic Price War: How a 71% Medicare Discount is Reshaping Healthcare Finance
A landmark 71% Medicare price cut on Ozempic and Wegovy signals a major shift in healthcare finance, impacting investors, the economy, and Big Pharma.
The Hundred-Billion-Dollar Pill: Inside Pfizer’s High-Stakes Gamble to Conquer the Weight-Loss Market
Pfizer is betting billions on an oral weight-loss pill to challenge Novo Nordisk and Eli Lilly’s injectable dominance in a market poised to hit $100B.
The Rybelsus Revelation: Why One Chart Correction Unlocks Novo Nordisk’s True Value
A minor chart correction for Novo Nordisk reveals a major lesson in financial analysis, highlighting the crucial difference between its diabetes and obesity drugs.